Guidelines for the restart of imiglucerase in patients with Gaucher disease: Recommendations from the European Working Group on Gaucher disease
Carla E. M. Hollak(Centre For Development Studies), Ari Zimran(Hebrew University of Jerusalem), Derralynn Hughes(Royal Free London NHS Foundation Trust), Helen Michelakakis(Institute of Child Health), Jeremy Manuel, Nadia Belmatoug(Hôpital Beaujon), Maja Di Rocco(Istituto Giannina Gaslini), Tanya Collin-Histed, Ashok Vellodi(Great Ormond Street Hospital), Bruno Bembi(University of Udine), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Pilar Giraldo(Université Paris-Saclay), Timothy M. Cox(University of Cambridge), Olaf A. Bodamer(Broad Institute), Patrick Deegan(Addenbrooke's Hospital), Elena Lukina, Johannes M. F. G. Aerts(Leiden University Medical Center)
Cited by 5
Related Papers
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|823
Thalassaemia
|The Lancet|2017|763
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535